Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity

Novel cancer escaping mechanisms

Masao Ichikawa, Lieping Chen

Research output: Contribution to journalArticle

Abstract

The majority of human and rodent cancers display various antigens which could elicit cellular and humoral immune responses. Such immunity, however, often fails to prevent progressive growth of cancers. It has long been speculated that tumor antigens may not be presented in appropriate fashion, which subsequently fails to elicit a strong immune response. Recent studies, however, indicate that immunization by formulated tumor antigens or even transfer of pre-activated T lymphocytes also have limited impact on cancer growth despite the fact that these methods could often enhance immune responses in cancer patients. These findings imply that even afferent arm of immunity are strengthen, it is not necessarily being translated to tumor regression. It is possible that the development of evasion mechanisms in tumor microenvironment play a critical role in the resistance of therapeutic immune responses. Recent studies provide compelling evidence that human and rodent cancers develop evasion mechanisms by aberrantly expressing normal proteins, which are required for normal tissue homeostasis, to either build a microenvironment locally or reach other organs systemically. In this review, we will focus our discussion on two recently described molecules, B7-H1 and B7-H4, in the context of their roles in the evasion of tumor immunity and possible approaches for therapeutic manipulation.

Original languageEnglish (US)
Pages (from-to)2856-2860
Number of pages5
JournalFrontiers in bioscience : a journal and virtual library
Volume10
Issue numberSUPPL. 3
StatePublished - 2005

Fingerprint

B7 Antigens
T-cells
Tumors
Immunity
Neoplasm Antigens
T-Lymphocytes
Molecules
Tissue homeostasis
Immunization
Neoplasms
Rodentia
Antigens
Tumor Microenvironment
Humoral Immunity
Growth
Cellular Immunity
Proteins
Homeostasis
Therapeutics

Keywords

  • B7-H1
  • B7-H4
  • CD137
  • Effecter Phase
  • Immunotherapy
  • PD-1
  • Review

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity : Novel cancer escaping mechanisms. / Ichikawa, Masao; Chen, Lieping.

In: Frontiers in bioscience : a journal and virtual library, Vol. 10, No. SUPPL. 3, 2005, p. 2856-2860.

Research output: Contribution to journalArticle

@article{df001e98dc1a4284becc88150c1b827d,
title = "Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: Novel cancer escaping mechanisms",
abstract = "The majority of human and rodent cancers display various antigens which could elicit cellular and humoral immune responses. Such immunity, however, often fails to prevent progressive growth of cancers. It has long been speculated that tumor antigens may not be presented in appropriate fashion, which subsequently fails to elicit a strong immune response. Recent studies, however, indicate that immunization by formulated tumor antigens or even transfer of pre-activated T lymphocytes also have limited impact on cancer growth despite the fact that these methods could often enhance immune responses in cancer patients. These findings imply that even afferent arm of immunity are strengthen, it is not necessarily being translated to tumor regression. It is possible that the development of evasion mechanisms in tumor microenvironment play a critical role in the resistance of therapeutic immune responses. Recent studies provide compelling evidence that human and rodent cancers develop evasion mechanisms by aberrantly expressing normal proteins, which are required for normal tissue homeostasis, to either build a microenvironment locally or reach other organs systemically. In this review, we will focus our discussion on two recently described molecules, B7-H1 and B7-H4, in the context of their roles in the evasion of tumor immunity and possible approaches for therapeutic manipulation.",
keywords = "B7-H1, B7-H4, CD137, Effecter Phase, Immunotherapy, PD-1, Review",
author = "Masao Ichikawa and Lieping Chen",
year = "2005",
language = "English (US)",
volume = "10",
pages = "2856--2860",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity

T2 - Novel cancer escaping mechanisms

AU - Ichikawa, Masao

AU - Chen, Lieping

PY - 2005

Y1 - 2005

N2 - The majority of human and rodent cancers display various antigens which could elicit cellular and humoral immune responses. Such immunity, however, often fails to prevent progressive growth of cancers. It has long been speculated that tumor antigens may not be presented in appropriate fashion, which subsequently fails to elicit a strong immune response. Recent studies, however, indicate that immunization by formulated tumor antigens or even transfer of pre-activated T lymphocytes also have limited impact on cancer growth despite the fact that these methods could often enhance immune responses in cancer patients. These findings imply that even afferent arm of immunity are strengthen, it is not necessarily being translated to tumor regression. It is possible that the development of evasion mechanisms in tumor microenvironment play a critical role in the resistance of therapeutic immune responses. Recent studies provide compelling evidence that human and rodent cancers develop evasion mechanisms by aberrantly expressing normal proteins, which are required for normal tissue homeostasis, to either build a microenvironment locally or reach other organs systemically. In this review, we will focus our discussion on two recently described molecules, B7-H1 and B7-H4, in the context of their roles in the evasion of tumor immunity and possible approaches for therapeutic manipulation.

AB - The majority of human and rodent cancers display various antigens which could elicit cellular and humoral immune responses. Such immunity, however, often fails to prevent progressive growth of cancers. It has long been speculated that tumor antigens may not be presented in appropriate fashion, which subsequently fails to elicit a strong immune response. Recent studies, however, indicate that immunization by formulated tumor antigens or even transfer of pre-activated T lymphocytes also have limited impact on cancer growth despite the fact that these methods could often enhance immune responses in cancer patients. These findings imply that even afferent arm of immunity are strengthen, it is not necessarily being translated to tumor regression. It is possible that the development of evasion mechanisms in tumor microenvironment play a critical role in the resistance of therapeutic immune responses. Recent studies provide compelling evidence that human and rodent cancers develop evasion mechanisms by aberrantly expressing normal proteins, which are required for normal tissue homeostasis, to either build a microenvironment locally or reach other organs systemically. In this review, we will focus our discussion on two recently described molecules, B7-H1 and B7-H4, in the context of their roles in the evasion of tumor immunity and possible approaches for therapeutic manipulation.

KW - B7-H1

KW - B7-H4

KW - CD137

KW - Effecter Phase

KW - Immunotherapy

KW - PD-1

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=21344456553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21344456553&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 2856

EP - 2860

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - SUPPL. 3

ER -